07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-196a (miR-196a); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc); homeobox B7 (HOXB7)

Cancer INDICATION: Breast cancer Studies in patient samples, cell culture and mice suggest miR-196a or inhibition of MYC could help treat tamoxifen-resistant breast cancer. In tumors from estrogen receptor-positive breast cancer patients previously treated with tamoxifen, high...
07:00 , Jun 30, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Homeobox B7 (HOXB7) In vitro, mouse and patient sample studies suggest antagonizing HOXB7 might help...
00:15 , Jun 9, 2007 |  BC Extra  |  Clinical News

Downregulation of kinase linked to heritable CLL

Researchers from the Ohio State University and colleagues reported in Cell that loss or reduced expression of death-associated protein kinase 1 ( DAPK1) was a primary susceptibility factor to heritable chronic lymphocytic leukemia (CLL)....
07:00 , Apr 9, 2001 |  BC Week In Review  |  Company News

Amplistar, Johns Hopkins University deal

Amplistar received an exclusive worldwide license from the university to ovarian-related gene products that stimulate an immune reaction in ovarian cancer patients. The license includes rights to the HOXB7 gene product, which researchers at...